Roche’s Tecentriq snags FDA label expansion in type of colon cancer

RegulatoryapprovedTecentriqPositive

AI Analysis

Summary

Roche's Tecentriq received FDA label expansion for deficient mismatch repair (dMMR) colon cancer, becoming the first immunotherapy specifically indicated for this cancer type associated with higher post-surgery progression risk.

Outcome Details

FDA label expansion for dMMR colon cancer

Importance:7/10

Sentiment:

0.80

FDA approvallabel expansionimmunotherapycolon cancerdMMRTecentriq

Related Companies

$RHHBY

Read the original article

Published by Pharmaceutical Technology on October 9, 2026 10:37 AM

Read Original